EHA 2025: Tripled Cardiac Morbidity Risk After Hodgkin Lymphoma Therapy

At EHA 2025, Dr. Sara Rossetti, MD, PhD from Rigshospitalet, Denmark, presented her study on cardiac morbidity in young Hodgkin lymphoma patients in Denmark. Her research highlights a threefold increased risk of cardiac complications, especially heart failure, compared to the general population, emphasizing the need for ongoing monitoring and further research on late treatment effects.